| 查看: 144 | 回复: 0 | |||
| 当前主题已经存档。 | |||
[交流]
Sanofi Obesity Drug Gets Final Okay From UK's NICE
|
|||
|
LONDON (Reuters) Jun 25 - Sanofi-Aventis won a final green light for its obesity drug Acomplia (rimonabant) from Britain's cost-effectiveness watchdog NICE on Wednesday, clearing the way for doctors to prescribe it on the state health service. The move was expected following a positive appraisal from the National Institute for Health and Clinical Excellence (NICE) in March. It marks a small positive for the French drugmaker's once much-hyped medicine, which has failed to live up to early expectations. NICE's final guidance recommends using Acomplia as an addition to diet and exercise for obese or overweight adults who don't respond to or are intolerant of two other weight-loss drugs, orlistat and sibutramine. But NICE cautioned that treatment should not continue beyond 6 months unless patients lost at least 5 percent of their initial body weight and there should, in any event, be a formal clinical assessment after 2 years. The UK decision contrasts with Germany where Acomplia is not reimbursed by health insurers because it is deemed simply to improve lifestyle. Acomplia was once touted as a multibillion-dollar seller, but hopes for the product dimmed last year when a U.S. expert panel recommended against its approval in the world's biggest market, after it was linked to rare cases of suicidal thoughts. Sanofi said in October it expected only limited sales of the drug in the next few years, until new clinical trial results testing it in diabetes are ready for submission to regulators in 2009. Worldwide sales of the drug were a meagre 79 million euros ($122.9 million) last year. Roche makes the older weight-loss drug orlistat under the brand name Xenical, while sibutramine is marketed by Abbott Laboratories under the brand names Meridia or Reductil. |
» 猜你喜欢
分子对接相关经验分享
已经有0人回复
分子对接相关经验分享
已经有0人回复
药物学论文润色/翻译怎么收费?
已经有246人回复
求助中国药典1995年版、二部
已经有0人回复
求大佬收留
已经有0人回复
北京协和医学院杰青课题组招聘科研助理
已经有0人回复
求助https://www.pnas.org/doi/10.1073/pnas.2535777123 全文
已经有0人回复
2026生物医药产业发展大会
已经有0人回复
国青中了
已经有23人回复
:D多个国家或地区的农药法规&登记情况查询网站
已经有0人回复











回复此楼